Antidepressant dosing for the acute treatment of unipolar depression

Primary Psychiatry

Volumn 16, Issue 10, 2009, Pages 30-36

  Solvason, Hugh Brent ^a   DeBattista, Charles ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; REVIEW;

EID: 75449101408     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68(suppl 10):8-10.
2. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164(8):1189-1197.
3. Physicians' Desk Reference. 64th ed. New York, NY: Thomson Reuters; 2009.
4. Mula M. Anticonvulsants - antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. 2008;9(8):730-737.
5. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28(4):619-626.
6. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269-275.
7. Flint AJ. Pharmacologic treatment of depression in late life. CMAJ. 1997;157(8):1061-1067.
8. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
9. Volonteri L, Colasanti A, Cerveri G, et al. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. J Psychopharmacol. April 30, 2009. [Epub ahead of print].
10. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatr Res. 2007;149(1-3):195-200.
11. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353.
12. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22(4):379-387.
13. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243- 1252.
14. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101-108.
15. Schatzberg A, Cole J, DeBattista C. Manual of Clinical Psychopharmacology. 6th ed. Arlington, VA: American Psychiatric Association; 2007.
16. Center for Disease Control and Prevention. "Health, United States, 2008 With Special Feature on Health in Young Adults". Washington, DEC: US Dept of Health and Human Services, National Center for Health Statistics; 2008
17. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848-856.
18. Leon AC. Are two antidepressant mechanisms better than one? Issues in clinical trial design and analysis. J Clin Psychiatry. 2004;65(suppl 4):31-36.
19. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006;21(3):159-169.
20. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007;23(6):1303-1318.
21. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2004;255(6):387-400.
22. Lundmark J, Scheel Thomsen I, Fjord-Larsen T, et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Pscyhiatr Scand Suppl. 1989;350:76-80.
23. Bayer AJ, Roberts NA, Allen EA, et al. The pharmacokinetics of paroxetine in the elderly. Acta Pscyhiatr Scand Suppl. 1989;350:85-86.
24. Kelly MW, Perry PJ, Holstad SG, Garvey MJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit. 1989;11(2):165-170.
25. Ronfeld RA, Wilner KD, Baris BA. Sertraline. Chronopharmacokinetics and the effect of coadministration with food. Clin Pharmacokinet. 1997;32(suppl 1):50-55.
26. Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31(1):42-56.
27. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57(5):503-509.
28. Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther. 2003;25(8):2138-2154.
29. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GE. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-199.
30. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res. 2006;40(4):337-348.
31. Delini-Stula A, Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol. 2000;15(4):255-260.
32. Lindauer A, Siepmann T, Oertel R, et al. Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. Clin Pharmacokinet. 2008;47(11):721-731.
33. Nakagawa A, Watanabe N, Omori IM, et al. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs. 2008;22(7):587-602.
34. Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008;8(12):1787-1797.
35. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Human Psychopharmacol. 2009;24(3):177-190.
36. Williams GO. Management of depression in the elderly. Prim Care. 1989;16(2):451-474.
37. Radziwon-Zaleska M, Matsumoto H, Skalski M, et al. Therapeutic tricyclic antidepressant drug monitoring in younger and older depressive patients. Pharmacol Rep. 2006;58(4):501-506.
38. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet. 1987;13(6):381-392.
39. Perry PJ, Alexander B. Rational use of antidepressants. Prim Care. 1987;14(4):773-783.
40. Ulrich S, Northoff G, Wurthmann C. Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: a therapeutic window relationship. Pharmacopsychiatry. 2001;34(1):33-40.
41. Preskorn SH. Should bupropion dosage be adjusted based on therapeutic drug monitoring. Psychopharmacol Bull. 1991;27(4):637-645.
42. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry. 1988;45(2):145-149.
43. Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Arch Gen Psychiatry. 1990;147(12):1690-1691.
44. Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother. 2009;10(10):1665-1673.
45. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl):5-18.